- Home
- WHF vs CYBN Comparison
WHF vs CYBN Comparison
Compare WHF & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- CYBN
- Stock Information
- Founded
- WHF 2011
- CYBN 2019
- Country
- WHF United States
- CYBN Canada
- Employees
- WHF N/A
- CYBN N/A
- Industry
- WHF Finance Companies
- CYBN Pharmaceuticals and Biotechnology
- Sector
- WHF Finance
- CYBN Health Care
- Exchange
- WHF Nasdaq
- CYBN Nasdaq
- Market Cap
- WHF 207.1M
- CYBN 176.5M
- IPO Year
- WHF 2012
- CYBN N/A
- Fundamental
- Price
- WHF $8.69
- CYBN $6.26
- Analyst Decision
- WHF Hold
- CYBN Strong Buy
- Analyst Count
- WHF 4
- CYBN 3
- Target Price
- WHF $10.00
- CYBN $85.00
- AVG Volume (30 Days)
- WHF 60.2K
- CYBN 617.3K
- Earning Date
- WHF 11-06-2025
- CYBN 08-13-2025
- Dividend Yield
- WHF 20.57%
- CYBN N/A
- EPS Growth
- WHF N/A
- CYBN N/A
- EPS
- WHF 0.15
- CYBN N/A
- Revenue
- WHF $81,499,000.00
- CYBN N/A
- Revenue This Year
- WHF N/A
- CYBN N/A
- Revenue Next Year
- WHF N/A
- CYBN N/A
- P/E Ratio
- WHF $56.72
- CYBN N/A
- Revenue Growth
- WHF N/A
- CYBN N/A
- 52 Week Low
- WHF $8.36
- CYBN $4.81
- 52 Week High
- WHF $12.42
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- WHF 54.39
- CYBN 40.40
- Support Level
- WHF $8.65
- CYBN $6.16
- Resistance Level
- WHF $8.78
- CYBN $6.73
- Average True Range (ATR)
- WHF 0.08
- CYBN 0.50
- MACD
- WHF 0.04
- CYBN -0.06
- Stochastic Oscillator
- WHF 74.29
- CYBN 21.74
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.